
Frank Ruschitzka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/465211/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200.	1.0	13,008
2	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	1.0	6,826
3	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	1.0	5,689
4	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
5	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	2.9	5,272
6	2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal, 2017, 38, 2739-2791.	1.0	5,142
7	Endothelial cell infection and endotheliitis in COVID-19. Lancet, The, 2020, 395, 1417-1418.	6.3	5,100
8	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.3	4,778
9	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	1.0	3,915
10	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2013, 34, 2281-2329.	1.0	2,176
11	Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. New England Journal of Medicine, 2015, 373, 929-938.	13.9	1,827
12	International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. European Heart Journal, 2018, 39, 2032-2046.	1.0	972
13	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2019, 40, 3297-3317.	1.0	944
14	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart Journal, 2015, 36, 657-668.	1.0	902
15	Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 8-27.	2.9	835
16	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
17	Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex. New England Journal of Medicine, 2013, 369, 1395-1405.	13.9	688
18	Acute heart transplant rejection due to Saint John's wort. Lancet, The, 2000, 355, 548-549.	6.3	682

#	Article	IF	CITATIONS
19	Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. New England Journal of Medicine, 2016, 375, 2519-2529.	13.9	607
20	The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 137-155.	2.9	605
21	Epidemiology and oneâ€year outcomes in patients with chronic heart failure and preserved, midâ€range and reduced ejection fraction: an analysis of the ESC Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2017, 19, 1574-1585.	2.9	568
22	Anti–Tumor Necrosis Factor-α Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis. Circulation, 2002, 106, 2184-2187.	1.6	559
23	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 1505-1535.	2.9	555
24	European Society of Cardiology Heart Failure Longâ€Term Registry (<scp>ESCâ€HFâ€LT</scp>): 1â€year followâ€up outcomes and differences across regions. European Journal of Heart Failure, 2016, 18, 613-625.	2.9	538
25	International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. European Heart Journal, 2018, 39, 2047-2062.	1.0	521
26	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 1169-1186.	2.9	490
27	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 226-241.	2.9	455
28	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 2019, 21, 715-731.	2.9	446
29	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	2.9	434
30	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 2018, 39, 26-35.	1.0	426
31	High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men. Circulation, 2002, 105, 1399-1402.	1.6	425
32	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet, The, 2020, 396, 1895-1904.	6.3	425
33	Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease. Circulation, 2003, 107, 405-409. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer	1.6	367
34	therapies: a position statement and new risk assessment tools from the <scp>C</scp> ardioâ€ <scp>O</scp> ncology <scp>S</scp> tudy <scp>G</scp> roup of the <scp>H</scp> eart <scp>F</scp> ailure <scp>A</scp> ssociation of the <scp>E</scp> uropean <scp>S</scp> ociety of <scp>C</scp> ardiology in collaboration with the <scp>I</scp> nternational	2.9	364
35	<pre><scp>C</scp>ardiology in contactor with the <scp>S</scp>ociety. European Journal of Heart Failure, 2020, Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the <scp>ESC</scp> Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2017, 19, 1242-1254.</pre>	2.9	339
36	Effects of ferric carboxymaltose on hospitalisations and mortality rates in ironâ€deficient heart failure patients: an individual patient data metaâ€analysis. European Journal of Heart Failure, 2018, 20, 125-133.	2.9	317

#	Article	IF	CITATIONS
37	Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet, The, 2004, 364, 347-354.	6.3	315
38	Recommendations on preâ€hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. European Journal of Heart Failure, 2015, 17, 544-558.	2.9	315
39	Mental Stress Induces Prolonged Endothelial Dysfunction via Endothelin-A Receptors. Circulation, 2002, 105, 2817-2820.	1.6	297
40	Contemporary Presentation and Management of Valvular Heart Disease. Circulation, 2019, 140, 1156-1169.	1.6	281
41	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. New England Journal of Medicine, 2017, 376, 1956-1964.	13.9	257
42	2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Pressure, 2018, 27, 314-340.	0.7	254
43	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the Furopean Society of Cardiology (ESC). European Journal of Heart Failure. 2017, 19, 821-836. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure.	2.9	252
44	implant and follow-up recommendations and management: A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in collaboration with the Heart Failure Society of America (HFSA), the American Society of Echocardiography (ASE), the American Heart Association (AHA), the European Association of Echocardiography (EAE) of the ESC and the Heart		

#	Article	IF	CITATIONS
55	Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis, 2020, 314, 58-62.	0.4	213
56	The role of ventricular–arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association. European Journal of Heart Failure, 2019, 21, 402-424.	2.9	202
57	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2020, 22, 391-412.	2.9	193
58	Differences in the Clinical Profile and Outcomes of Typical and Atypical Takotsubo Syndrome. JAMA Cardiology, 2016, 1, 335.	3.0	189
59	Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. European Heart Journal, 2018, 39, 4277-4284.	1.0	189
60	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€Oncology Council of the European Society of Cardiology</scp> . European Journal of Heart Failure, 2020, 22, 1966-1983.	2.9	184
61	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European Journal of Heart Failure, 2013, 15, 1082-1094.	2.9	182
62	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	2.9	182
63	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	1.0	171
64	Acute heart failure congestion and perfusion status–Âimpact of the clinical classification on inâ€hospital and longâ€term outcomes; insights from the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2019, 21, 1338-1352.	2.9	170
65	Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2016, 18, 1096-1105.	2.9	160
66	Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. EClinicalMedicine, 2020, 25, 100449.	3.2	155
67	Acetaminophen Increases Blood Pressure in Patients With Coronary Artery Disease. Circulation, 2010, 122, 1789-1796.	1.6	146
68	A novel clinical score (<scp>InterTAK</scp> Diagnostic Score) to differentiate takotsubo syndrome from acute coronary syndrome: results from the International Takotsubo Registry. European Journal of Heart Failure, 2017, 19, 1036-1042.	2.9	142
69	Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. European Heart Journal, 2016, 37, 2823-2829.	1.0	136
70	Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. European Heart Journal, 2013, 34, 3515-3524.	1.0	132
71	Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. European Journal of Heart Failure, 2018, 20, 199-215.	2.9	128
72	Differential Effects of Selective Cyclooxygenase-2 Inhibitors on Endothelial Function in Salt-Induced Hypertension. Circulation, 2003, 108, 2308-2311.	1.6	127

#	Article	IF	CITATIONS
73	COVID-19 Illness and HeartÂFailure. JACC: Heart Failure, 2020, 8, 512-514.	1.9	127
74	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	1.0	123
75	Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. American Heart Journal, 2009, 157, 606-612.	1.2	115
76	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2017, 19, 1361-1378.	2.9	115
77	Celecoxib Decreases Endothelial Tissue Factor Expression Through Inhibition of c-Jun Terminal NH 2 Kinase Phosphorylation. Circulation, 2005, 111, 1685-1689.	1.6	111
78	Loss of AngiomiR-126 and 130a in Angiogenic Early Outgrowth Cells From Patients With Chronic Heart Failure. Circulation, 2012, 126, 2962-2975.	1.6	111
79	ECG Criteria to Differentiate Between Takotsubo (Stress) Cardiomyopathy and Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	1.6	111
80	Indications and practical approach to non-invasive ventilation in acute heart failure. European Heart Journal, 2018, 39, 17-25.	1.0	111
81	Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis. Circulation, 2008, 117, 2262-2269.	1.6	108
82	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how?. European Journal of Heart Failure, 2018, 20, 1039-1051.	2.9	107
83	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. European Heart lournal, 2015, 36, 1958-1966.	1.0	105
84	Cardiovascular effects of flavanol-rich chocolate in patients with heart failure. European Heart Journal, 2012, 33, 2172-2180.	1.0	104
85	First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. American Journal of Transplantation, 2020, 20, 2876-2882.	2.6	102
86	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. European Journal of Heart Failure, 2020, 22, 2349-2369.	2.9	101
87	Sodium–glucose coâ€transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1495-1503.	2.9	100
88	Simvastatin improves endothelial function in patients with rheumatoid arthritis. Journal of the American College of Cardiology, 2005, 45, 461-464.	1.2	99
89	Management of heart failure patients with <scp>COVID</scp> â€19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 941-956.	2.9	95
90	Takotsubo cardiomyopathy has a unique cardiac biomarker profile: NT-proBNP/myoglobin and NT-proBNP/troponin T ratios for the differential diagnosis of acute coronary syndromes and stress induced cardiomyopathy. International Journal of Cardiology, 2012, 154, 328-332.	0.8	93

#	Article	IF	CITATIONS
91	SARS-CoV-2 leads to a small vessel endotheliitis in the heart. EBioMedicine, 2021, 63, 103182.	2.7	93
92	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289.	2.9	92
93	<i>PTX3</i> Polymorphisms and Invasive Mold Infections After Solid Organ Transplant: Figure 1 Clinical Infectious Diseases, 2015, 61, 619-622.	2.9	91
94	Retinal microvascular dysfunction in heart failure. European Heart Journal, 2018, 39, 47-56.	1.0	91
95	Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. European Journal of Heart Failure, 2019, 21, 844-851.	2.9	91
96	Integration of a palliative approach into heart failure care: a <scp>European Society of Cardiology Heart Failure Association</scp> position paper. European Journal of Heart Failure, 2020, 22, 2327-2339.	2.9	88
97	Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis – implications for cardiovascular safety. International Journal of Cardiology, 2013, 168, 2453-2461.	0.8	86
98	Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus) Tj ETQq0 0 (38, 3282-3292.	0 rgBT /Ovei	rloc <u>k 1</u> 0 Tf 50
99	Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. European Journal of Heart Failure, 2021, 23, 1858-1871.	2.9	86
100	Right Ventricular Failure: Pathophysiology, Diagnosis and Treatment. Cardiac Failure Review, 2019, 5, 140-146.	1.2	85
101	Exercise training in patients with ventricular assist devices: a review of the evidence and practical advice. A position paper from the Committee on Exercise Physiology and Training and the Committee of Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 3-13.	2.9	84
102	Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESCâ€HFAâ€EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 1378-1389.	2.9	83
103	Sex―and ageâ€related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 92-102.	2.9	81
104	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. European Heart Journal, 2019, 40, 2142-2151.	1.0	79
105	Aldosterone Receptor Antagonism Normalizes Vascular Function in Liquorice-Induced Hypertension. Hypertension, 2001, 37, 801-805.	1.3	78
106	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. European Heart Journal, 2021, 42, 1254-1269.	1.0	78
107	Torcetrapib impairs endothelial function in hypertension. European Heart Journal, 2012, 33, 1615-1624.	1.0	75
108	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. European Journal of Heart Failure, 2013, 15, 947-959.	2.9	75

#	Article	IF	CITATIONS
109	Takotsubo cardiomyopathy: still much more to learn. Heart, 2014, 100, 1804-1812.	1.2	75
110	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. Circulation, 2019, 139, 413-415.	1.6	75
111	Upgrading to resynchronization therapy after chronic right ventricular pacing improves left ventricular remodelling. European Heart Journal, 2010, 31, 1477-1485.	1.0	74
112	Traditional and new composite endpoints inÂheart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal of Heart Failure, 2016, 18, 482-489.	2.9	74
113	Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 1615-1633.	2.9	74
114	Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume) Tj ETQq0 0 0	rgBT/Ove	erlo၄န္ဒ 10 Tf 50
115	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. European Heart Journal, 2021, 42, 3011-3020.	1.0	71
116	Erythropoietinâ€induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB Journal, 2003, 17, 259-261.	0.2	70
117	Dysfunctional Baroreflex Regulation of Sympathetic Nerve Activity in Patients With Vasovagal Syncope. Circulation, 2003, 107, 1620-1625.	1.6	70
118	Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. European Heart Journal, 2012, 33, 1589-1597.	1.0	70
119	Interleukin-1β Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor. Journal of Clinical Medicine, 2019, 8, 2072.	1.0	70
120	Longâ€term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2018, 20, 332-341.	2.9	69
121	Endothelial dysfunction in cardiovascular disease and Flammer syndrome—similarities and differences. EPMA Journal, 2017, 8, 99-109.	3.3	68
122	Cocoa, Blood Pressure, and Vascular Function. Frontiers in Nutrition, 2017, 4, 36.	1.6	68
123	From abstract to impact in cardiovascular research: factors predicting publication and citation. European Heart Journal, 2012, 33, 3034-3045.	1.0	66
124	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodium–glucose coâ€ŧransporter 2 inhibitors in heart failure. European Journal of Heart Failure, 2020, 22, 1984-1986.	2.9	66
125	The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. European Heart Journal, 2015, 36, 1983-1989.	1.0	65
126	Statins and the Risk of Cancer After Heart Transplantation. Circulation, 2012, 126, 440-447.	1.6	64

#	Article	IF	CITATIONS
127	Electron microscopy of SARS-CoV-2: a challenging task – Authors' reply. Lancet, The, 2020, 395, e100.	6.3	64
128	Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry. Journal of the American Heart Association, 2019, 8, e010881.	1.6	63
129	New devices in heart failure: an European Heart Rhythm Association report: Developed by the European Heart Rhythm Association; Endorsed by the Heart Failure Association. Europace, 2014, 16, 109-128.	0.7	62
130	Selective COX-2 Inhibitors and Renal Injury in Salt-Sensitive Hypertension. Hypertension, 2005, 45, 193-197.	1.3	61
131	Inâ€hospital worsening heart failure. European Journal of Heart Failure, 2015, 17, 1104-1113.	2.9	60
132	First magnetic resonance imaging-guided cardiac radioablation of sustained ventricular tachycardia. Radiotherapy and Oncology, 2020, 152, 203-207.	0.3	59
133	Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). European Heart Journal, 2017, 38, ehw387.	1.0	58
134	Comprehensive inâ€hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2018, 20, 1081-1099.	2.9	57
135	Psoriasis and atherosclerosis: two plaques, one syndrome?. European Heart Journal, 2012, 33, 1989-1991.	1.0	54
136	Endothelial SIRT6 blunts stroke size and neurological deficit by preserving blood–brain barrier integrity: a translational study. European Heart Journal, 2020, 41, 1575-1587.	1.0	54
137	Takotsubo Recurrence. Journal of the American College of Cardiology, 2019, 73, 982-984.	1.2	53
138	Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. American Journal of Medicine, 2021, 134, 482-489.	0.6	53
139	Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy. European Heart Journal, 2014, 35, 1051-1060.	1.0	52
140	BK Polyomavirus-Specific 9mer CD8 T Cell Responses Correlate With Clearance of BK Viremia in Kidney Transplant Recipients: First Report From the Swiss Transplant Cohort Study. American Journal of Transplantation, 2017, 17, 2591-2600.	2.6	52
141	Endothelin 1 Type A Receptor Antagonism Prevents Vascular Dysfunction and Hypertension Induced by 11β-Hydroxysteroid Dehydrogenase Inhibition. Circulation, 2001, 103, 3129-3135.	1.6	51
142	Superresponse to Cardiac Resynchronization Therapy. Circulation, 2014, 130, 87-90.	1.6	50
143	Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Failure, 2018, 5, 257-266.	1.4	50
144	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and highâ€risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1298-1314.	2.9	50

#	Article	IF	CITATIONS
145	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. European Heart Journal, 2020, 41, 3255-3268.	1.0	49
146	Different Effects of Thrombin Receptor Activation on Endothelium and Smooth Muscle Cells of Human Coronary Bypass Vessels. Circulation, 1997, 95, 1870-1876.	1.6	49
147	Pulmonary vein isolation using a higher power shorter duration CLOSE protocol with a surround flow ablation catheter. Journal of Cardiovascular Electrophysiology, 2019, 30, 2199-2204.	0.8	48
148	Coffee Blunts Mental Stress–Induced Blood Pressure Increase in Habitual but Not in Nonhabitual Coffee Drinkers. Hypertension, 2005, 46, 521-526.	1.3	47
149	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 181-195.	2.9	47
150	Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thrombosis Research, 2009, 123, 460-465.	0.8	43
151	Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial. European Heart Journal, 2016, 37, 49-59.	1.0	43
152	Association of intraventricular mechanical dyssynchrony with response to cardiac resynchronization therapy in heart failure patients with a narrow QRS complex. European Heart Journal, 2010, 31, 3054-3062.	1.0	42
153	Rationale and design of the AFFIRMâ€AHF trial: a randomised, doubleâ€blind, placeboâ€controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in ironâ€deficient patients admitted for acute heart failure. European Journal of Heart Failure, 2019, 21, 1651-1658.	2.9	42
154	Age-Related Variations in Takotsubo Syndrome. Journal of the American College of Cardiology, 2020, 75, 1869-1877.	1.2	42
155	Endothelial Dysfunction in Acute Renal Failure. Journal of the American Society of Nephrology: JASN, 1999, 10, 953-962.	3.0	42
156	Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and Hypertension. Current Hypertension Reports, 2012, 14, 304-309.	1.5	40
157	Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Medicine, 2020, 18, 103.	2.3	40
158	GuÃa ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114.	0.6	40
159	Impact of Renal Impairment on Beta-Blocker Efficacy in PatientsÂWithÂHeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2893-2904.	1.2	39
160	Cardiovascular Effects of Coffee: Is It a Risk Factor?. Progress in Cardiovascular Nursing, 2005, 20, 65-69.	0.5	38
161	Rationale and design of the CONFIRMâ€HF study: a doubleâ€blind, randomized, placeboâ€controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Failure, 2014, 1, 52-58.	1.4	38
162	Polymorphisms in the lectin pathway of complement activation influence the incidence ofÂacute rejection and graft outcome after kidneyÂtransplantation. Kidney International, 2016, 89, 927-938.	2.6	37

#	Article	IF	CITATIONS
163	Reconstituted HDL in Acute Coronary Syndromes. Cardiovascular Therapeutics, 2012, 30, e51-7.	1.1	36
164	Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 859-868.	2.9	36
165	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESCâ€EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 1424-1437.	2.9	36
166	Haemodynamically irrelevant pericardial effusion is associated with increased mortality in patients with chronic heart failure. European Heart Journal, 2013, 34, 1414-1423.	1.0	35
167	Sacubitril/valsartan eligibility and outcomes in the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGMâ€HF trial, ESC guidelines, and real world. European Journal of Heart Failure, 2019, 21, 1383-1397.	2.9	35
168	Effects of endothelin on hemodynamics, prostaglandins, blood coagulation and renal function. Kidney International, 1995, 47, 795-801.	2.6	34
169	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 279-287.	1.1	34
170	Tissue Endothelin-Converting Enzyme Activity Correlates With Cardiovascular Risk Factors in Coronary Artery Disease. Circulation, 2000, 102, 1086-1092.	1.6	33
171	Cardiovascular risk of cyclooxygenaseâ€2 inhibitors and traditional nonâ€steroidal antiâ€inflammatory drugs. Annals of Medicine, 2007, 39, 18-27.	1.5	32
172	ls the panic about beta-blockers in perioperative care justified?. European Heart Journal, 2014, 35, 2442-2444.	1.0	32
173	Prognostic value of longâ€ŧerm blood pressure changes in patients with chronic heart failure. European Journal of Heart Failure, 2017, 19, 837-842.	2.9	32
174	Vasopeptidase Inhibition Restores Renovascular Endothelial Dysfunction in Salt-Induced Hypertension. Journal of the American Society of Nephrology: JASN, 2001, 12, 2280-2287.	3.0	32
175	Rationale for and design of the <scp>TRUEâ€AHF</scp> trial: the effects of ularitide on the shortâ€ŧerm clinical course and longâ€ŧerm mortality of patients with acute heart failure. European Journal of Heart Failure, 2017, 19, 673-681.	2.9	31
176	Interaction of systolic blood pressure and resting heart rate with clinical outcomes in takotsubo syndrome: insights from the International Takotsubo Registry. European Journal of Heart Failure, 2018, 20, 1021-1030.	2.9	31
177	Higher prevalence of pulmonary macrothrombi in <scp>SARSâ€CoV</scp> â€2 than in influenza A: autopsy results from â€~Spanish flu' 1918/1919 in Switzerland to Coronavirus disease 2019. Journal of Pathology: Clinical Research, 2021, 7, 135-143.	1.3	29
178	Angiotensin receptor blockers: baseline therapy in hypertension?. European Heart Journal, 2009, 30, 2427-2430.	1.0	28
179	Isolated right ventricular ballooning syndrome: a new variant of transient cardiomyopathy. European Heart Journal, 2011, 32, 1821-1821.	1.0	27
180	Cardiac implantable electronic devices with a defibrillator component and allâ€cause mortality in left ventricular assist device carriers: results from the PCHFâ€VAD registry. European Journal of Heart Failure, 2019, 21, 1129-1141.	2.9	27

#	Article	IF	CITATIONS
181	Clinical Predictors and Prognostic Impact of Recovery of Wall Motion Abnormalities in Takotsubo Syndrome: Results From the International Takotsubo Registry. Journal of the American Heart Association, 2019, 8, e011194.	1.6	27
182	Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. European Journal of Preventive Cardiology, 2022, 29, 1352-1360.	0.8	26
183	Heart failure in COVIDâ€19: the multicentre, multinational PCHFâ€COVICAV registry. ESC Heart Failure, 2021, 8, 4955-4967.	1.4	26
184	Cardiac resynchronization therapy in patients with a narrow QRS. Current Heart Failure Reports, 2009, 6, 49-56.	1.3	25
185	To the Heart of the Matter. Circulation, 2005, 112, 941-945.	1.6	24
186	Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection?. European Heart Journal, 2012, 33, 1996-1998.	1.0	24
187	Surviving 20 Years After Heart Transplantation: A Success Story. Annals of Thoracic Surgery, 2014, 97, 499-504.	0.7	24
188	Pulmonary vein isolation using ablation index vs. CLOSE protocol with a surround flow ablation catheter. Europace, 2020, 22, 84-89.	0.7	24
189	Impact of aspirin on takotsubo syndrome: a propensity scoreâ€based analysis of the InterTAK Registry. European Journal of Heart Failure, 2020, 22, 330-337.	2.9	24
190	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology ―Heart Failure Association EURObservational Research Programme Heart Failure Longâ€Term Registry. ESC Heart Failure, 2020, 7, 2098-2112.	1.4	23
191	The Heart Failure Association Atlas: rationale, objectives, and methods. European Journal of Heart Failure, 2020, 22, 638-645.	2.9	23
192	Donor-specific anti-HLA antibodies detected by Luminex: predictive for short-term but not long-term survival after heart transplantation. Transplant International, 2013, 26, 1097-1107.	0.8	22
193	European Cardiac Resynchronization Therapy Survey II: rationale and design. Europace, 2015, 17, 137-141.	0.7	22
194	Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial. European Heart Journal, 2017, 38, ehw506.	1.0	22
195	Retinal microvascular dysfunction in hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 1523-1531.e2.	0.6	22
196	Cocoa, Blood Pressure, and Vascular Function. Current Hypertension Reports, 2012, 14, 279-284.	1.5	21
197	â€~heartfailurematters.org', an educational website for patients and carers from the Heart Failure Association of the European Society of Cardiology: objectives, use and future directions. European Journal of Heart Failure, 2017, 19, 1447-1454.	2.9	21
198	Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial. Journal of the American Heart Association, 2018, 7, .	1.6	20

#	Article	IF	CITATIONS
199	Retinal microvascular dysfunction in patients with coronary artery disease with and without heart failure: a <i>continuum</i> ?. European Journal of Heart Failure, 2019, 21, 988-997.	2.9	20
200	Prediction of short―and longâ€ŧerm mortality in takotsubo syndrome: the InterTAK Prognostic Score. European Journal of Heart Failure, 2019, 21, 1469-1472.	2.9	20
201	Deletion of fibroblast activation protein provides atheroprotection. Cardiovascular Research, 2021, 117, 1060-1069.	1.8	20
202	Guidance on the management of left ventricular assist device <scp>(LVAD)</scp> supported patients for the nonâ€ <scp>LVAD</scp> specialist healthcare provider: executive summary. European Journal of Heart Failure, 2021, 23, 1597-1609.	2.9	20
203	Influence of aldosterone vs endothelin receptor antagonism on renovascular function in liquoriceâ€induced hypertension. Nephrology Dialysis Transplantation, 2001, 16, 2146-2151.	0.4	19
204	Peripartum Cardiomyopathy With Cardiogenic Shock: Recovery After Prolactin Inhibition and Mechanical Support. Annals of Thoracic Surgery, 2011, 91, 274-276.	0.7	19
205	Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases. European Journal of Heart Failure, 2017, 19, 449-456.	2.9	19
206	Safety and Efficacy of Transcatheter Aortic Valve Replacement With Continuation of Vitamin K Antagonists or Direct Oral Anticoagulants. JACC: Cardiovascular Interventions, 2021, 14, 135-144.	1.1	19
207	Adult T-cells impair neonatal cardiac regeneration. European Heart Journal, 2022, 43, 2698-2709.	1.0	19
208	Postischemic Administration of IL-1α Neutralizing Antibody Reduces Brain Damage and Neurological Deficit in Experimental Stroke. Circulation, 2020, 142, 187-189.	1.6	18
209	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Europace, 2021, 23, 1324-1342.	0.7	18
210	Impact of Atrial Fibrillation on Outcome in Takotsubo Syndrome: Data From the International Takotsubo Registry. Journal of the American Heart Association, 2021, 10, e014059.	1.6	18
211	Assessment of Artificial Intelligence in Echocardiography Diagnostics in Differentiating Takotsubo Syndrome From Myocardial Infarction. JAMA Cardiology, 2022, 7, 494.	3.0	18
212	Acute heart failure: lessons learned, roads ahead. European Journal of Heart Failure, 2018, 20, 842-850.	2.9	17
213	Successful support of biventricular heart failure patients by new EXCOR® Adult pumps with bileaflet valves: a prospective study. Clinical Research in Cardiology, 2018, 107, 413-420.	1.5	17
214	TNFâ€Î± antagonism rescues the effect of ageing on stroke: Perspectives for targeting inflammâ€ageing. European Journal of Clinical Investigation, 2021, 51, e13600.	1.7	17
215	True Anemia―Red Blood Cell Volume Deficit―in Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	16
216	Endothelin antagonists and heart failure. Current Hypertension Reports, 2002, 4, 85-92.	1.5	15

#	Article	IF	CITATIONS
217	Shear stress-dependent platelet function after LDL cholesterol apheresis. Thrombosis Research, 2004, 113, 395-398.	0.8	15
218	Lyme Carditis. Cardiology in Review, 2004, 12, 185-187.	0.6	15
219	Beyond dyspnoea as an endpoint in acute heart failure trials. European Heart Journal, 2011, 32, 1442-1445.	1.0	15
220	Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections. BMC Infectious Diseases, 2016, 16, 321.	1.3	15
221	The BET Protein Inhibitor Apabetalone Rescues Diabetes-Induced Impairment of Angiogenic Response by Epigenetic Regulation of Thrombospondin-1. Antioxidants and Redox Signaling, 2022, 36, 667-684.	2.5	15
222	Characteristics, management, and outcomes of patients with multiple native valvular heart disease: a substudy of the EURObservational Research Programme Valvular Heart Disease II Survey. European Heart Journal, 2022, 43, 2756-2766.	1.0	15
223	Happy birthday European Heart Journal: in 30 years, from Cinderella to centre stage. European Heart Journal, 2010, 31, 1945-1950.	1.0	14
224	Survival, quality of life and impact of right heart failure in patients with acute cardiogenic shock treated with ECMO. Heart and Lung: Journal of Acute and Critical Care, 2016, 45, 409-415.	0.8	14
225	Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes. Journal of the American College of Cardiology, 2018, 71, 1325-1333.	1.2	14
226	Epicardial adipose tissue volume is associated with adverse outcomes after transcatheter aortic valve replacement. International Journal of Cardiology, 2019, 286, 29-35.	0.8	14
227	Cardiovascular magnetic resonance T2* mapping for structural alterations in hypertrophic cardiomyopathy. European Journal of Radiology Open, 2019, 6, 78-84.	0.7	14
228	Myocardial edema in COVID-19 on cardiac MRI. Journal of Heart and Lung Transplantation, 2020, 39, 730-732.	0.3	14
229	MMP-2 knockdown blunts age-dependent carotid stiffness by decreasing elastin degradation and augmenting eNOS activation. Cardiovascular Research, 2022, 118, 2385-2396.	1.8	14
230	Absenteeism and presenteeism in healthcare workers due to respiratory illness. Infection Control and Hospital Epidemiology, 2021, 42, 268-273.	1.0	14
231	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 2022, 43, 863-867.	1.0	14
232	Sirtuin 5 promotes arterial thrombosis by blunting the fibrinolytic system. Cardiovascular Research, 2021, 117, 2275-2288.	1.8	13
233	Clinical predictors of left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy. American Heart Journal, 2020, 223, 34-43.	1.2	13
234	Impact of Genetic Variant Reassessment on the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy Based on the 2010 Task Force Criteria. Circulation Genomic and Precision Medicine, 2021, 14, e003047.	1.6	13

#	Article	IF	CITATIONS
235	TNFα induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNFα antibodies. Cardiovascular Research, 2022, 118, 254-266.	1.8	13
236	Vasopeptidase inhibitors—concepts and evidence. Nephrology Dialysis Transplantation, 2001, 16, 1532-1535.	0.4	12
237	The Blue Man. Circulation, 2006, 113, e63.	1.6	12
238	The Year in Cardiology 2013: heart failure. European Heart Journal, 2014, 35, 470-473.	1.0	12
239	SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration. Ophthalmologica, 2017, 238, 205-216.	1.0	12
240	Plasma testosterone and arrhythmic events in male patients with arrhythmogenic right ventricular cardiomyopathy. ESC Heart Failure, 2020, 7, 1547-1559.	1.4	12
241	Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 2006, 349, 597-603.	1.0	11
242	Novel anti-inflammatory drugs in hypertension. Nephrology Dialysis Transplantation, 2006, 21, 859-864.	0.4	11
243	Anti-VEGF Therapies and Blood Pressure: More Than Meets the Eye. Current Hypertension Reports, 2010, 12, 33-38.	1.5	11
244	NTâ€proBNP Provides Incremental Prognostic Information in Cardiac Outpatients With and Without Echocardiographic Findings. Clinical Cardiology, 2011, 34, 183-188.	0.7	11
245	The future of continuing medical education: the roles of medical professional societies and the health care industry. European Heart Journal, 2019, 40, 1720-1727.	1.0	11
246	Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. American Heart Journal, 2020, 228, 98-108.	1.2	11
247	Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5â€year analysis within the Swiss Transplant Cohort study. Transplant Infectious Disease, 2020, 22, e13289.	0.7	11
248	Destination therapy – time for a paradigm change in heart failure therapy. Swiss Medical Weekly, 2013, 143, w13729.	0.8	11
249	The best of the European Heart Journal: look back with pride. European Heart Journal, 2012, 33, 1161-1171.	1.0	10
250	Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy. Europace, 2017, 19, 1848-1854.	0.7	10
251	HFA of the ESC position paper on the management of LVADâ€supported patients for the nonâ€LVAD specialist healthcare provider Part 3: at the hospital and discharge. ESC Heart Failure, 2021, 8, 4425-4443.	1.4	10
252	Outcome of inter-hospital transfer of patients on extracorporeal membrane oxygenation in Switzerland. Swiss Medical Weekly, 2019, 149, w20054.	0.8	10

#	Article	IF	CITATIONS
253	Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 611-621.	1.4	10
254	Improved survival of left ventricular assist device carriers in <scp>Europe</scp> according to implantation eras: results from the <scp>PCHFâ€VAD</scp> registry. European Journal of Heart Failure, 2022, 24, 1305-1315.	2.9	10
255	Methylation of the Hippo effector YAP by the methyltransferase SETD7 drives myocardial ischaemic injury: a translational study. Cardiovascular Research, 2023, 118, 3374-3385.	1.8	10
256	The challenge of nonresponders to cardiac resynchronization therapy: Lessons learned from oncology. Heart Rhythm, 2012, 9, S14-S17.	0.3	9
257	Finerenone in heart failure: walking a fine line. European Heart Journal, 2016, 37, 2115-2117.	1.0	9
258	Heart failure specialization in Europe. European Journal of Heart Failure, 2016, 18, 347-349.	2.9	9
259	Prognostic value of texture analysis from cardiac magnetic resonance imaging in patients with Takotsubo syndrome: a machine learning based proof-of-principle approach. Scientific Reports, 2020, 10, 20537.	1.6	9
260	Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study. Infection Control and Hospital Epidemiology, 2022, 43, 312-318.	1.0	9
261	Improving 1-year mortality prediction in ACS patients using machine learning. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 855-865.	0.4	9
262	Comprehensive cardiac resynchronization therapy optimization in the real world. Cardiology Journal, 2014, 21, 316-324.	0.5	9
263	Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Doubleâ€Blind, Randomized, Placeboâ€Controlled Trial. Clinical Cardiology, 2016, 39, 285-290.	0.7	8
264	Positive emotions and Takotsubo syndrome: â€~happy heart' or â€~Diagoras' syndrome?. European Heart Journal, 2016, 37, 2821-2822.	1.0	8
265	Management of allergy transfer upon solid organ transplantation. American Journal of Transplantation, 2020, 20, 834-843.	2.6	8
266	Evaluation of Myocardial Gene Expression Profiling for Superior Diagnosis of Idiopathic Giant-Cell Myocarditis and Clinical Feasibility in a Large Cohort of Patients with Acute Cardiac Decompensation. Journal of Clinical Medicine, 2020, 9, 2689.	1.0	8
267	Effect of daily 2000 IU versus 800 IU vitamin D on blood pressure among adults age 60 years and older: a randomized clinical trial. American Journal of Clinical Nutrition, 2020, 112, 527-537.	2.2	8
268	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. ESC Heart Failure, 2021, 8, 1924-1932.	1.4	8
269	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. Clinical Research in Cardiology, 2022, 111, 186-196.	1.5	8
270	Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy. Open Heart, 2020, 7, e001152.	0.9	8

#	Article	IF	CITATIONS
271	Changes in serum biomarker profiles after percutaneous mitral valve repair with the MitraClip system. Cardiology Journal, 2016, 23, 384-392.	0.5	8
272	Soluble ST2 – a new biomarker in heart failure. Cardiovascular Medicine(Switzerland), 0, , .	0.1	8
273	Impact of a nationwide COVID-19 lockdown on acute coronary syndrome referrals. Cardiology Journal, 2020, 27, 633-635.	0.5	8
274	Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial. American Heart Journal, 2022, 247, 33-41.	1.2	8
275	Vasopeptidase inhibition: Effective blood pressure control for vascular protection. Current Hypertension Reports, 2002, 4, 78-84.	1.5	7
276	Darusentan: a new perspective for treatment of resistant hypertension?. Expert Opinion on Investigational Drugs, 2008, 17, 1255-1263.	1.9	7
277	Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 231-240.	1.0	7
278	The wealth of nations and the dissemination of cardiovascular research. International Journal of Cardiology, 2013, 169, 190-195.	0.8	7
279	Allograft vasculopathy vs. coronary artery disease: comparison by optical coherence tomography. European Heart Journal, 2013, 34, 137-137.	1.0	7
280	Clinical benefits and safety of renal denervation in severe arterial hypertension: A longâ€ŧerm followâ€up study. Journal of Clinical Hypertension, 2020, 22, 1854-1864.	1.0	7
281	Familial dilated cardiomyopathy associated with a novel heterozygous RYR2 early truncating variant. Cardiology Journal, 2021, 28, 173-175.	0.5	7
282	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist deviceâ€supported patients for the nonâ€left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. ESC Heart Failure, 2021, 8, 4409-4424.	1.4	7
283	Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments. Swiss Medical Weekly, 2016, 146, w14295.	0.8	7
284	Efficacy of Catheter Ablation for Atrial Arrhythmias in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy—A Multicenter Study. Journal of Clinical Medicine, 2021, 10, 4962.	1.0	7
285	Predictors of left atrial fibrosis in patients with atrial fibrillation referred for catheter ablation. Cardiology Journal, 2022, 29, 413-422.	0.5	7
286	Painful lessons: COX-2 inhibitors, NSAIDs, and hypertension. Current Hypertension Reports, 2007, 9, 41-44.	1.5	6
287	Endothelin-receptor antagonists in arterial hypertension: Further indications?. Current Hypertension Reports, 2007, 9, 59-65.	1.5	6
288	The <i>European Heart Journal</i> and the <i>European Journal of Heart Failure</i> : partners in scientific publishing. European Journal of Heart Failure, 2012, 14, 1075-1082.	2.9	6

#	Article	IF	CITATIONS
289	3D fusion of coronary CT angiography and CT myocardial perfusion imaging: Intuitive assessment of morphology and function. Journal of Cardiovascular Computed Tomography, 2017, 11, 437-443.	0.7	6
290	Hypovolemia and reduced hemoglobin mass in patients with heart failure and preserved ejection fraction. Physiological Reports, 2019, 7, e14222.	0.7	6
291	Anti-inflammatory strategies in hypertension: Focus on COX-1 and COX-2. Current Hypertension Reports, 2005, 7, 52-60.	1.5	5
292	Vitamin D and hypertension. Current Hypertension Reports, 2008, 10, 49-51.	1.5	5
293	Evidence for improvement in survival with antihypertensive combination treatment. Journal of Hypertension, 2011, 29, S9-S14.	0.3	5
294	Long-Term Performance of Modern Coronary Sinus Leads in Cardiac Resynchronization Therapy. Indian Pacing and Electrophysiology Journal, 2014, 14, 112-120.	0.3	5
295	Recurrent Clotting of a Continuous-Flow Right Ventricular Assist Device—Repeated Thrombolysis With Two Different Protocols. Journal of Cardiothoracic and Vascular Anesthesia, 2015, 29, 1614-1617.	0.6	5
296	Prognostic value of mean pulmonary artery pressure in the stable phase after heart transplantation. European Journal of Cardio-thoracic Surgery, 2017, 52, 775-780.	0.6	5
297	Effect of cardiac resynchronization therapy in patients with diabetes randomized in <scp>EchoCRT</scp> . European Journal of Heart Failure, 2017, 19, 80-87.	2.9	5
298	The year in cardiology 2017: heart failure. European Heart Journal, 2018, 39, 832-839.	1.0	5
299	Improving Selection of Mitraclip Candidates in Advanced Chronic Heart Failure: Look Right to Predict Right. Journal of Cardiac Failure, 2019, 25, 312-313.	0.7	5
300	Vascular endothelial growth factor D is a biomarker of fluid overload in haemodialysis patients. Nephrology Dialysis Transplantation, 2021, 36, 529-536.	0.4	5
301	Prognostic value of inflammatory biomarkers and GRACE score for cardiac death and acute kidney injury after acute coronary syndromes. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 445-452.	0.4	5
302	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the nonâ€hospital settings in the community. ESC Heart Failure, 2021, 8, 4394-4408.	1.4	5
303	Working together in cardiovascular prevention: the common mission of the <i>European Heart Journal</i> and the <i>European Journal of Preventive Cardiology</i> . European Journal of Preventive Cardiology, 2012, 19, 1217-1226.	0.8	4
304	The European Heart Journal on the move: can scientific publishing be further improved?. European Heart Journal, 2013, 34, 409-415.	1.0	4
305	Cardiac manifestation of polyarteritis nodosa. European Heart Journal, 2018, 39, 2603-2603.	1.0	4
306	Pulsatile arterial blood pressure mimicking aortic valve opening during continuous-flow LVAD support: a case report. Journal of Cardiothoracic Surgery, 2019, 14, 219.	0.4	4

#	Article	IF	CITATIONS
307	Differential effect of cardiac resynchronization therapy in patients with diabetes mellitus: a longâ€term retrospective cohort study. ESC Heart Failure, 2020, 7, 2773-2783.	1.4	4
308	Cyclosporine C0- versus C2-monitoring over three years in maintenance heart transplantation. Swiss Medical Weekly, 2011, 141, w13149.	0.8	4
309	EARTH: Endothelin _A Receptor Antagonist Trial in Heart Failure. Cardiology, 2001, 1, 294-298.	0.3	3
310	The year in cardiology: heart failure 2014. European Heart Journal, 2015, 36, 421-424.	1.0	3
311	Mitral interventions in heart failure: time to deliver on the promise. European Journal of Heart Failure, 2018, 20, 609-611.	2.9	3
312	Multimodal Multiparametric Three-dimensional Image Fusion in Coronary Artery Disease: Combining the Best of Two Worlds. Radiology: Cardiothoracic Imaging, 2020, 2, e190116.	0.9	3
313	The FAST-FURO study: effect of very early administration of intravenous furosemide in the prehospital setting to patients with acute heart failure attending the emergency department. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 487-496.	0.4	3
314	Pericardial effusion unrelated to surgery is a predictor of mortality in heart transplant patients. Cardiology Journal, 2018, 25, 714-721.	0.5	3
315	C-reactive protein influences shear stress-dependent platelet adhesion in patients with familiar hypercholesterolemia and coronary artery disease undergoing LDL apheresis. Thrombosis and Haemostasis, 2006, 96, 540-2.	1.8	3
316	Diagnosis of acute heart failure in CT pulmonary angiography: feasibility and accuracy. European Radiology, 2022, , 1.	2.3	3
317	Are selective cyclo-oxygenase 2 inhibitors safe after coronary artery bypass grafting surgery?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 504-505.	3.3	2
318	Auricall®. A new device for a non-invasive, wireless, continuous monitoring of oxygen saturation and heart rate in patients with heart failure. International Journal of Cardiology, 2008, 129, 141-143.	0.8	2
319	Darusentan in Resistant Hypertension: Lost in Translation. Current Hypertension Reports, 2010, 12, 1-3.	1.5	2
320	In search of improved therapies for acute heart failure. Nature Reviews Cardiology, 2011, 8, 9-10.	6.1	2
321	The year in cardiology 2015: heart failure. European Heart Journal, 2016, 37, 437-441.	1.0	2
322	Right ventricular only pacing for cardiac resynchronization therapy. Europace, 2022, 24, 70-71.	0.7	2
323	Long-term follow-up after cardiac resynchronization therapy-optimization in a real-world setting: A single-center cohort study. Cardiology Journal, 2021, 28, 728-737.	0.5	2
324	Treatment of Advanced Heart Failure—Focus on Transplantation and Durable Mechanical Circulatory Support. Heart Failure Clinics, 2021, 17, 697-708.	1.0	2

#	Article	IF	CITATIONS
325	"Real world" experience in Cardiac Resynchronization Therapy at a Swiss Tertiary Care Center. Swiss Medical Weekly, 2017, 147, w14425.	0.8	2
326	Postprocedural Troponin Elevation and Mortality After Transcatheter Aortic Valve Implantation. Journal of the American Heart Association, 2021, 10, e020739.	1.6	2
327	Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis. ESC Heart Failure, 2022, 9, 1186-1194.	1.4	2
328	Baseline Predictors of Renal Failure in Transcatheter Aortic Valve Implantation. Journal of Invasive Cardiology, 2019, 31, E289-E297.	0.4	2
329	Vasopeptidase Inhibitors: A New Class of Drugs. Cardiology, 2001, 1, 96-102.	0.3	1
330	â€~Class effect' amongst cardiac drugs: term of convenience or pharmacological reality?. International Journal of Clinical Practice, 2005, 60, 2-5.	0.8	1
331	Peri-infarct pacing to prevent left reverse remodelling: an unvalidated concept?. European Heart Journal, 2016, 37, 494-495.	1.0	1
332	The year in cardiology 2016: heart failure. European Heart Journal, 2017, 38, ehw638.	1.0	1
333	Ageâ€dependent impairment of the erythropoietin response to reduced central venous pressure in HFpEF patients. Physiological Reports, 2019, 7, e14021.	0.7	1
334	Effects of hemodialysis on blood volume, macro- and microvascular function. Microvascular Research, 2020, 129, 103958.	1.1	1
335	Blood Pressure-Lowering Therapy. Handbook of Experimental Pharmacology, 2020, , 1.	0.9	1
336	Preâ€ŧransplant Social Adaptability Index and clinical outcomes in renal transplantation: The Swiss Transplant Cohort study. Clinical Transplantation, 2021, 35, e14218.	0.8	1
337	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Failure, 2014, 1, n/a-n/a.	1.4	1
338	Acute heart and brain failure: a case report. European Heart Journal - Case Reports, 2020, 4, 1-8.	0.3	1
339	Cardiac amyloidosis. Cardiovascular Medicine(Switzerland), 0, , .	0.1	1
340	The subcutaneous implantable cardioverter defibrillator in daily clinical practice. Swiss Medical Weekly, 2017, 147, w14518.	0.8	1
341	Fiftieth anniversary of the first heart transplantation in Switzerland in the context of the worldwide history of heart transplantation. Swiss Medical Weekly, 2020, 150, w20192.	0.8	1
342	Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. American Journal of Hypertension, 2004, 17, S243.	1.0	0

#	Article	IF	CITATIONS
343	Response to Letter Regarding Article, "Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis― Circulation, 2008, 118, .	1.6	Ο
344	The BEAUTIFUL study: Is heart rate reduction a new therapeutic principle?. Current Hypertension Reports, 2009, 11, 45-47.	1.5	0
345	Is There a Link Between Angiotensin Receptor Blockers and Cancer?. Current Hypertension Reports, 2011, 13, 5-7.	1.5	Ο
346	Response to Letters Regarding Article, "Statins and the Risk of Cancer After Heart Transplantation― Circulation, 2013, 127, e442.	1.6	0
347	Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex. New England Journal of Medicine, 2014, 370, 578-581.	13.9	0
348	Reply to Cunha et al. Clinical Infectious Diseases, 2015, 61, 1894-1895.	2.9	0
349	EHJ's new impact factor of 15.2: a global strategy is paying off. European Heart Journal, 2015, 36, 2763-2766.	1.0	0
350	Henry Krum, Pioneering Heart Failure Researcher. European Journal of Heart Failure, 2016, 18, 125-126.	2.9	0
351	HeartFailureNews, new inEJHF. European Journal of Heart Failure, 2016, 18, 451-451.	2.9	0
352	Reply to Letter to the Editor "Endothelial dysfunction in Takotsubo syndrome― International Journal of Cardiology, 2017, 234, 102.	0.8	0
353	Reply: Impact of Cardio-Renal Syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up. International Journal of Cardiology, 2018, 258, 206.	0.8	0
354	The effect of oxygen in Sirt3-mediated myocardial protection: a proof-of-concept study in cultured cardiomyoblasts. Journal of Thrombosis and Thrombolysis, 2018, 46, 102-112.	1.0	0
355	Exercise intolerance — from spiroergometry to transdiaphragmatic myocardial punch biopsy: a case report of isolated cardiac sarcoidosis. European Heart Journal - Case Reports, 2021, 5, ytaa121.	0.3	0
356	Outcome of Patients With Severe Aortic Stenosis and Normal Coronary Arteries Undergoing Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2021, 143, 89-96.	0.7	0
357	Accuracy of dynamic three-dimensional magnetic resonance perfusion imaging for the detection of coronary artery disease in patients with reduced ejection fraction. Imaging, 2021, 13, 61-68.	0.3	0
358	Use of induction therapy in pediatric heart transplant recipients in Switzerland – Analysis of the Swiss national database. Transplant Immunology, 2021, 68, 101443.	0.6	0
359	Effectiveness of cardiovascular implantable electronic devices with a defibrillator component therapy according to ventricular assist device implant strategy: data from the PCHF-VAD registry. Cardiologia Croatica, 2018, 13, 358-360.	0.0	0
360	Cardiac amyloidosis. Cardiovascular Medicine(Switzerland), 0, , .	0.1	0

#	Article	IF	CITATIONS
361	Professor Willibald Maier. European Heart Journal, 2021, 42, 881-881.	1.0	0
362	FastTrack: a key success factor for the European Heart Journal. European Heart Journal, 2014, 35, 1983-90.	1.0	0
363	581â€fVentricular–arterial coupling derived from proximal aortic stiffness and aerobic capacity across the heart failure spectrum. European Heart Journal Supplements, 2021, 23, .	0.0	Ο